Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875196 | 1.00 | THRB (0.50) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL13609140 | 1.00 | THRB (0.50) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL15384163 | 1.00 | THRB (0.50) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL7035553 | 1.00 | THRB (0.50) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL15384166 | 1.00 | THRB (0.50) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL875853 | 0.97 | — | — | |
| SCHEMBL27806651 | 0.95 | HTT (0.58) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL28224346 | 0.89 | TSHR (0.48) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL440055 | 0.89 | — | — | |
| SCHEMBL12614042 | 0.89 | ALDH1A1 (0.35) | THRBHTTMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113200826-B | Synthesis method of polymethoxy dialkyl ether | 军事科学院系统工程研究院军事新能源技术研究所 | 2022-07-19 | — | — | CN | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20200148646-A1 | 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550088-B2 | 6-substituted and 7-substituted morphinan analogs and the use thereof | PURDUE PHARMA L.P. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2951160-B1 | BENZOMORPHAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2931729-B1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | PURDUE PHARMA LP (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20140163058-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014087226-A1 | BUPRENORPHINE ANALOGS AS OPIOD RECEPTOR MODULATORS | PURDUE PHARMA L.P. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140135351-A1 | Benzomorphan Analogs and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014072809-A2 | BENZOMORPHAN ANALOGS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2013167963-A1 | BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130274173-A1 | STABLE HELICAL IONIC POLYPEPTIDES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-17 | — | — | US | disclosed |
| EP-0744411-B1 | Halomethylation of polymer | BAYER INC (CA) | 2003-03-05 | — | — | EP | disclosed |
| US-5629386-A | Halomethylation of polymer | BAYER RUBBER INC. (CA) | 1997-05-13 | — | — | US | disclosed |
| EP-0744411-A2 | Halomethylation of polymer | Bayer Rubber Inc. (CA) | 1996-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148646-A1 | 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF | OPRL1, OPRM1, OPRD1 | THRB 337/4885HTT 2255/4885MEN1 4043/4885 |
| US-10550088-B2 | 6-substituted and 7-substituted morphinan analogs and the use thereof | OPRL1, OPRM1, OPRD1 | THRB 337/4885HTT 2255/4885MEN1 4043/4885 |
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | THRB 184/4885HTT 631/4885MEN1 4632/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | THRB 81/4885HTT 602/4885MEN1 4727/4885 |
| US-20130274173-A1 | STABLE HELICAL IONIC POLYPEPTIDES | GHITM, SLC7A1, PICALM | THRB 2383/4885HTT 1968/4885MEN1 1325/4885 |
| US-20140135351-A1 | Benzomorphan Analogs and the Use Thereof | OPRL1, OPRD1, OPRM1 | THRB 416/4885HTT 4030/4885MEN1 4555/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | THRB 184/4885HTT 631/4885MEN1 4632/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | THRB 184/4885HTT 631/4885MEN1 4632/4885 |
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | OPRL1, OPRD1, OPRK1 | THRB 223/4885HTT 4414/4885MEN1 4742/4885 |
| US-20140163058-A1 | BUPRENORPHINE ANALOGS | OPRL1, OPRK1, OPRD1 | THRB 90/4885HTT 2647/4885MEN1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.